Barclays lowered the firm’s price target on BioCryst (BCRX) to $9 from $11 and keeps an Equal Weight rating on the shares. The company reported an inline Q3 for Orladeyo with narrowed guidance, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX: